Medicines Co. upgraded to sector perform by RBC

RBC Capital Markets analyst Jason Kantor upgraded The Medicines Co. to sector perform, above average risk, from underperform on news of positive data from the Acuity trial. The analyst increased 2006 U.S. sales forecasts to $198.2 million from $193.8 million and earnings-per-share estimates to $0.29 from $0.18. Development and potential commercial success of Cangrelor and Clevelox will be important to offset concerns of possible revenue loss in 2010, if Angiomax loses patent protection, according to the analyst. Shares of the Parsippany, N.J.-based pharmaceutical company were up 81 cents, or 4.83%, at $17.57 on volume of 198,585 shares versus the three-month running average of 307,347 shares. (Nasdaq: MDCO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.